Juan Ramirez
Nurse Practitioner · Miami, FLNPI 1770976912
Payments from drug & device makers
Across 123 payments — averaging $35.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$950
- Amgen$478
- Boehringer Ingelheim$356
- Lilly USA, LLC$265
- Insulet Corporation$264
- Tandem Diabetes Care, Inc.$240
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $950 |
| Amgen | 13 | $478 |
| Boehringer Ingelheim | 4 | $356 |
| Lilly USA, LLC | 9 | $265 |
| Insulet Corporation | 2 | $264 |
| Tandem Diabetes Care, Inc. | 6 | $240 |
| Abbott | 10 | $206 |
| Corcept Therapeutics | 10 | $203 |
| Xeris Pharmaceuticals, Inc. | 10 | $194 |
| Dexcom, Inc. | 3 | $168 |
| AstraZeneca | 3 | $166 |
| Bayer | 4 | $162 |
| Ascendis Pharma Endocrinology Inc | 1 | $122 |
| Gilead | 1 | $68 |
| Novartis | 3 | $56 |
| Recordati_rare_diseases_inc. | 2 | $52 |
| IBSA Pharma Inc. | 2 | $48 |
| GSK | 2 | $39 |
| Pfizer | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Averitas Pharma Inc. | 1 | $31 |
| Dynavax Technologies Corporation | 1 | $26 |
| Sequel Med Tech, LLC | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Radius Health, Inc. | 1 | $22 |
| Cequr Corporation | 1 | $21 |
| Medtronic | 1 | $21 |
| Halozyme Inc | 1 | $21 |
| Merck | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,355 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 169 | $201,387 |
| OzempicSemaglutide | 156 | $145,557 |
| FarxigaDapagliflozin Propanediol | 101 | $130,669 |
| TrulicityDulaglutide | 73 | $85,641 |
| MounjaroTirzepatide | 60 | $65,224 |
| VascepaIcosapent Ethyl | 46 | $34,162 |
| Tresiba Flextouch U-100Insulin Degludec | 66 | $32,194 |
| TradjentaLinagliptin | 26 | $26,551 |
| RybelsusSemaglutide | 11 | $21,768 |
| JanuviaSitagliptin Phosphate | 15 | $19,996 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 178 | $17,418 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 30 | $15,147 |
| Novolog FlexpenInsulin Aspart | 86 | $14,439 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $12,989 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 163 | $12,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $356 | $227,938195 claims |
| Novo NordiskOzempic, Rybelsus | $950 | $167,325167 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $265 | $150,865133 claims |
| AstraZenecaFarxiga | $166 | $130,669101 claims |
| MerckJanuvia, Janumet Xr | $21 | $28,73228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Miami
- Margarita FernandezMiami$311K
- Maya BloombergMiami$202K
- Haydee KapinMiami$97K
- Terri PollackMiami$59K
- Amber FederizoMiami$39K
- Patricia Novoa-VogtMiami$35K
- Moriane JosephMiami$23K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.